Healthcare Asia on MSN4mon
What factors challenge the global N95 respirators market?
Rising availability of counterfeit products poses a challenge to the global N95 respirators market ... The lack of stringent ...
Nature3y
Advancing first-in-class anti-infective therapies to combat multidrug resistance
Infectious diseases are a major cause of global ... infections and are considered one of the top ten public health threats worldwide. Nosopharm is on a mission to discover and develop first-in ...
Business Wire1mon
Clarametyx Biosciences Awarded a Multi-Phased Agreement With CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial Infections
Clarametyx is developing a novel non-antibiotic and pathogen-agnostic therapeutic and vaccine platform to address persistent bacterial infections and combat the global threat of antibiotic resistance.